# Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

> **NCT05607810** · — · ACTIVE_NOT_RECRUITING · sponsor: **Adverum Biotechnologies, Inc.** · enrollment: 22 (estimated)

## Conditions studied

- Diabetic Macular Edema
- Diabetic Retinopathy

## Interventions

- **GENETIC:** ADVM-022

## Key facts

- **NCT ID:** NCT05607810
- **Lead sponsor:** Adverum Biotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-10
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05607810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05607810, "Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05607810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*